Which has higher earnings & valuation, EWTX or TRAX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than First Tracks Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A

Is EWTX or TRAX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% First Tracks Biotherapeutics N/A N/A N/A

Is TRAX or RLAY more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A Relay Therapeutics N/A -42.27% -38.67%

Does the media prefer TRAX or RLAY?

In the previous week, First Tracks Biotherapeutics had 11 more articles in the media than Relay Therapeutics. MarketBeat recorded 21 mentions for First Tracks Biotherapeutics and 10 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.66 beat First Tracks Biotherapeutics' score of 0.59 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment First Tracks Biotherapeutics 10 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Relay Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TRAX or TNGX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Tango Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A Tango Therapeutics N/A -25.75% -23.36%

Does the media refer more to TRAX or TNGX?

In the previous week, First Tracks Biotherapeutics had 18 more articles in the media than Tango Therapeutics. MarketBeat recorded 21 mentions for First Tracks Biotherapeutics and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.07 beat First Tracks Biotherapeutics' score of 0.59 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment First Tracks Biotherapeutics 10 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Tango Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, TRAX or TLX?

First Tracks Biotherapeutics has higher earnings, but lower revenue than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A Telix Pharmaceuticals $803.79M 4.50 -$7.12M N/A N/A

Is TRAX or TLX more profitable?

Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A Telix Pharmaceuticals N/A N/A N/A

First Tracks Biotherapeutics (TRAX) Competitors

$36.04 +1.91 (+5.60%)

Closing price 04:00 PM Eastern

Extended Trading

$35.66 -0.38 (-1.05%)

As of 07:56 PM Eastern

Compare

TRAX vs. EWTX, RLAY, TNGX, ABCL, and TLX

Should you buy First Tracks Biotherapeutics stock or one of its competitors? First Tracks Biotherapeutics's main competitors and comparable companies include Edgewise Therapeutics (EWTX), Relay Therapeutics (RLAY), Tango Therapeutics (TNGX), AbCellera Biologics (ABCL), and Telix Pharmaceuticals (TLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does First Tracks Biotherapeutics compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, First Tracks Biotherapeutics had 15 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 21 mentions for First Tracks Biotherapeutics and 6 mentions for Edgewise Therapeutics. First Tracks Biotherapeutics' average media sentiment score of 0.59 beat Edgewise Therapeutics' score of 0.04 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
First Tracks Biotherapeutics	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than First Tracks Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

Edgewise Therapeutics currently has a consensus price target of $51.33, suggesting a potential upside of 38.66%. First Tracks Biotherapeutics has a consensus price target of $67.67, suggesting a potential upside of 98.26%. Given First Tracks Biotherapeutics' higher probable upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

First Tracks Biotherapeutics' return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
First Tracks Biotherapeutics	N/A	N/A	N/A

Summary

First Tracks Biotherapeutics beats Edgewise Therapeutics on 7 of the 9 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Relay Therapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

First Tracks Biotherapeutics has higher earnings, but lower revenue than Relay Therapeutics. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
Relay Therapeutics	$15.35M	243.55	-$276.48M	-$1.57	N/A

First Tracks Biotherapeutics' return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Relay Therapeutics	N/A	-42.27%	-38.67%

First Tracks Biotherapeutics presently has a consensus target price of $67.67, indicating a potential upside of 98.26%. Relay Therapeutics has a consensus target price of $25.92, indicating a potential upside of 51.91%. Given First Tracks Biotherapeutics' higher possible upside, equities research analysts plainly believe First Tracks Biotherapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

97.0% of Relay Therapeutics shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, First Tracks Biotherapeutics had 11 more articles in the media than Relay Therapeutics. MarketBeat recorded 21 mentions for First Tracks Biotherapeutics and 10 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.66 beat First Tracks Biotherapeutics' score of 0.59 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
First Tracks Biotherapeutics	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Relay Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Relay Therapeutics beats First Tracks Biotherapeutics on 7 of the 12 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Tango Therapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

79.0% of Tango Therapeutics shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

First Tracks Biotherapeutics' return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Tango Therapeutics	N/A	-25.75%	-23.36%

In the previous week, First Tracks Biotherapeutics had 18 more articles in the media than Tango Therapeutics. MarketBeat recorded 21 mentions for First Tracks Biotherapeutics and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.07 beat First Tracks Biotherapeutics' score of 0.59 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
First Tracks Biotherapeutics	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Tango Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

First Tracks Biotherapeutics presently has a consensus price target of $67.67, indicating a potential upside of 98.26%. Tango Therapeutics has a consensus price target of $43.46, indicating a potential upside of 95.86%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe First Tracks Biotherapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

First Tracks Biotherapeutics has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than First Tracks Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
Tango Therapeutics	$62.38M	59.98	-$101.59M	-$0.85	N/A

Summary

Tango Therapeutics beats First Tracks Biotherapeutics on 6 of the 11 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

First Tracks Biotherapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. First Tracks Biotherapeutics' return on equity of 0.00% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
First Tracks Biotherapeutics	N/A	N/A	N/A

AbCellera Biologics currently has a consensus price target of $13.89, suggesting a potential upside of 12.28%. First Tracks Biotherapeutics has a consensus price target of $67.67, suggesting a potential upside of 98.26%. Given First Tracks Biotherapeutics' higher possible upside, analysts plainly believe First Tracks Biotherapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

First Tracks Biotherapeutics has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than First Tracks Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	50.48	-$146.41M	-$0.54	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, First Tracks Biotherapeutics had 10 more articles in the media than AbCellera Biologics. MarketBeat recorded 21 mentions for First Tracks Biotherapeutics and 11 mentions for AbCellera Biologics. First Tracks Biotherapeutics' average media sentiment score of 0.59 beat AbCellera Biologics' score of 0.49 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
First Tracks Biotherapeutics	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

First Tracks Biotherapeutics beats AbCellera Biologics on 7 of the 13 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Telix Pharmaceuticals?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Telix Pharmaceuticals	N/A	N/A	N/A

First Tracks Biotherapeutics has higher earnings, but lower revenue than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
Telix Pharmaceuticals	$803.79M	4.50	-$7.12M	N/A	N/A

In the previous week, First Tracks Biotherapeutics had 14 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 21 mentions for First Tracks Biotherapeutics and 7 mentions for Telix Pharmaceuticals. First Tracks Biotherapeutics' average media sentiment score of 0.59 beat Telix Pharmaceuticals' score of 0.32 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
First Tracks Biotherapeutics	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

First Tracks Biotherapeutics currently has a consensus target price of $67.67, suggesting a potential upside of 98.26%. Telix Pharmaceuticals has a consensus target price of $20.50, suggesting a potential upside of 92.49%. Given First Tracks Biotherapeutics' higher probable upside, equities research analysts plainly believe First Tracks Biotherapeutics is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

First Tracks Biotherapeutics beats Telix Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

Get First Tracks Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRAX vs. The Competition

Export

Metric	First Tracks Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.22B	$3.96B	$7.42B	$12.93B
Dividend Yield	N/A	3.65%	2.52%	19.59%
P/E Ratio	N/A	12.51	274.96	25.38
Price / Sales	N/A	1,206.02	609.32	90.34
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	N/A	15.79	10.32	6.02
Net Income	N/A	-$22.69M	$3.49B	$380.68M
7 Day Performance	12.59%	-4.31%	-2.54%	-3.01%
1 Month Performance	-6.32%	-11.49%	-6.87%	-5.59%
1 Year Performance	N/A	4.54%	1.81%	-5.23%

First Tracks Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRAX First Tracks Biotherapeutics	2.7747 of 5 stars	$36.04 +5.6%	$67.67 +87.8%	N/A	$1.22B	N/A	N/A	104	News Coverage Analyst Forecast
EWTX Edgewise Therapeutics	2.7355 of 5 stars	$39.15 -0.2%	$51.33 +31.1%	+151.8%	$4.25B	N/A	N/A	127	Analyst Forecast
RLAY Relay Therapeutics	2.4154 of 5 stars	$18.24 +4.7%	$25.92 +42.1%	+182.9%	$4.00B	$10.35M	N/A	192	Positive News
TNGX Tango Therapeutics	1.9323 of 5 stars	$23.60 +4.6%	$43.46 +84.2%	+155.1%	$3.98B	$62.38M	N/A	137
ABCL AbCellera Biologics	1.8764 of 5 stars	$12.68 +5.4%	$13.38 +5.5%	+120.1%	$3.89B	$66.17M	N/A	562	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRAX) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

First Tracks Biotherapeutics (TRAX) Competitors

TRAX vs. EWTX, RLAY, TNGX, ABCL, and TLX

How does First Tracks Biotherapeutics compare to Edgewise Therapeutics?

Summary

How does First Tracks Biotherapeutics compare to Relay Therapeutics?

Summary

How does First Tracks Biotherapeutics compare to Tango Therapeutics?

Summary

How does First Tracks Biotherapeutics compare to AbCellera Biologics?

Summary

How does First Tracks Biotherapeutics compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAX vs. The Competition

First Tracks Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

First Tracks Biotherapeutics (TRAX) Competitors

TRAX vs. EWTX, RLAY, TNGX, ABCL, and TLX

How does First Tracks Biotherapeutics compare to Edgewise Therapeutics?

Does the media refer more to EWTX or TRAX?

Which has higher earnings & valuation, EWTX or TRAX?

Do analysts rate EWTX or TRAX?

Is EWTX or TRAX more profitable?

Summary

How does First Tracks Biotherapeutics compare to Relay Therapeutics?

Which has higher earnings & valuation, TRAX or RLAY?

Is TRAX or RLAY more profitable?

Do analysts recommend TRAX or RLAY?

Do institutionals and insiders believe in TRAX or RLAY?

Does the media prefer TRAX or RLAY?

Summary

How does First Tracks Biotherapeutics compare to Tango Therapeutics?

Do institutionals & insiders believe in TRAX or TNGX?

Is TRAX or TNGX more profitable?

Does the media refer more to TRAX or TNGX?

Do analysts recommend TRAX or TNGX?

Which has preferable valuation & earnings, TRAX or TNGX?

Summary

How does First Tracks Biotherapeutics compare to AbCellera Biologics?

Is ABCL or TRAX more profitable?

Do analysts recommend ABCL or TRAX?

Which has preferable earnings & valuation, ABCL or TRAX?

Do institutionals & insiders hold more shares of ABCL or TRAX?

Does the media favor ABCL or TRAX?

Summary

How does First Tracks Biotherapeutics compare to Telix Pharmaceuticals?

Is TRAX or TLX more profitable?

Which has higher earnings and valuation, TRAX or TLX?

Does the media favor TRAX or TLX?

Do analysts prefer TRAX or TLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAX vs. The Competition

First Tracks Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools